DRUG (Bright Minds Biosciences) Beginning Cash Position: $64.90 Mil (As of Mar. 2026)


DRUG Bright Minds Biosciences Inc DRUG
34 GF Score
Price $77.84
! 2 Warning Signs
View Full Analysis

What is Bright Minds Biosciences Beginning Cash Position?

Bright Minds Biosciences DRUG -0.46% 34 Beginning Cash Position is $64.90 Mil as of Mar. 2026. GuruFocus rates DRUG with a GF Score™ of 34/100. The stock has 2 warning signs investors should review.

Bright Minds Biosciences's Beginning Cash Position for the quarter that ended in Mar. 2026 was $64.90 Mil.

Bright Minds Biosciences's quarterly Beginning Cash Position increased from Sep. 2025 ($37.15 Mil) to Dec. 2025 ($60.10 Mil) and increased from Dec. 2025 ($60.10 Mil) to Mar. 2026 ($64.90 Mil).

Bright Minds Biosciences's annual Beginning Cash Position declined from Sep. 2023 ($8.59 Mil) to Sep. 2024 ($4.98 Mil) and declined from Sep. 2024 ($4.98 Mil) to Sep. 2025 ($4.14 Mil).

Bright Minds Biosciences Beginning Cash Position Related Terms

Bright Minds Biosciences Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Bright Minds Biosciences's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bright Minds Biosciences Beginning Cash Position Chart

Bright Minds Biosciences Annual Data
Trend Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Beginning Cash Position
Get a 7-Day Free Trial 0.63 14.81 8.59 4.98 4.14

Bright Minds Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 40.33 40.74 37.15 60.10 64.90
DRUG
34GF Score
Bright Minds Biosciences Inc DRUG
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bright Minds Biosciences Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $64.90 Mil mean?
Bright Minds Biosciences (DRUG) has a Beginning Cash Position of $64.90 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Bright Minds Biosciences and its competitors.
Is Bright Minds Biosciences' Beginning Cash Position too high?
Bright Minds Biosciences' current Beginning Cash Position is $64.90 Mil. Overall, Bright Minds Biosciences has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Bright Minds Biosciences' Beginning Cash Position compare to VRTX and REGN?
Bright Minds Biosciences' Beginning Cash Position of $64.90 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Bright Minds Biosciences and its competitors. Bright Minds Biosciences's current Beginning Cash Position is $64.90 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bright Minds Biosciences stock overvalued right now?
Bright Minds Biosciences (DRUG) has a current Beginning Cash Position of $64.90 Mil. The current Beginning Cash Position is $64.90 Mil. Bright Minds Biosciences' overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Bright Minds Biosciences (DRUG), the current Beginning Cash Position is $64.90 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bright Minds Biosciences Business Description

Other Exchanges DRUG:Canada
Address 19 Vestry Street, New York, NY, USA, 10013
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
34GF Score

Get the complete analysis for DRUG

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$77.84
Price